EP
ESPR

Essential Partners’s Esperion Therapeutics ESPR Stock Holding History

Essential Partners’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-213
Closed -$584 – 2889
2026
Q1 		$584 Hold
213
– – ﹤0.01% 2389
2025
Q4 		$788 Hold
213
– – ﹤0.01% 2103
2025
Q3 		$564 Buy
+213
New +$412 ﹤0.01% 2179

Other funds holding ESPR

GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TC
Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.58% 1-Year Est. Return
OBAM
ODDO BHF Asset Management Paris, France $2.16B AUM 43.32% 1-Year Est. Return

Essential Partners's ESPR Position: Q2 2026 in Review

Essential Partners sold out of Esperion Therapeutics (ESPR) in Q2 2026, closing a stake of 213 shares — an estimated $584 sold.

Essential Partners first reported a position in ESPR in Q3 2025 and held it in 3 quarters. The position peaked at $788 in Q4 2025. 191 funds tracked by Wall St. Rank hold ESPR as of Q2 2026.

  • Essential Partners reported no remaining Esperion Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Essential Partners sold 213 Esperion Therapeutics shares in Q2 2026, an estimated $584.
  • Essential Partners first reported a position in Esperion Therapeutics in Q3 2025 and held it in 3 quarters.
  • Essential Partners's Esperion Therapeutics position peaked at $788 in Q4 2025.
  • 191 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2026.

Based on Essential Partners's 13F filing for Q2 2026, filed 10 Aug 2026.